Fengcai Zhu to Middle Aged
This is a "connection" page, showing publications Fengcai Zhu has written about Middle Aged.
Connection Strength
0.167
-
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther. 2021 07 15; 6(1):271.
Score: 0.015
-
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021 06; 27(6):1062-1070.
Score: 0.015
-
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 02; 21(2):181-192.
Score: 0.015
-
COVID-19 outbreak following a single patient exposure at an entertainment site: An epidemiological study. Transbound Emerg Dis. 2021 Mar; 68(2):773-781.
Score: 0.014
-
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 08 15; 396(10249):479-488.
Score: 0.014
-
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 06 13; 395(10240):1845-1854.
Score: 0.014
-
Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance and seroconversion in hepatitis B e antigen-negative chronic infection patients: A population-based prospective cohort. J Viral Hepat. 2018 12; 25(12):1588-1598.
Score: 0.013
-
Preliminary fast diagnosis of severe fever with thrombocytopenia syndrome with clinical and epidemiological parameters. PLoS One. 2017; 12(7):e0180256.
Score: 0.012
-
The early-onset febrile reaction following vaccination and associated factors: An exploratory sub-study based on the Ebola vaccine clinical trial. Hum Vaccin Immunother. 2017 06 03; 13(6):1-6.
Score: 0.011
-
Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults. Vaccine. 2014 Jun 17; 32(29):3706-12.
Score: 0.009
-
A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009 Dec 17; 361(25):2414-23.
Score: 0.007
-
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China. J Infect Dis. 2020 08 04; 222(5):746-754.
Score: 0.004
-
Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020 08; 285:198005.
Score: 0.004
-
Association of viral load with serum biomakers among COVID-19 cases. Virology. 2020 07; 546:122-126.
Score: 0.004
-
Establishment and development of national community-based collaborative innovation demonstration areas to achieve the control target of hepatitis B in China. BMC Infect Dis. 2019 Jul 12; 19(1):617.
Score: 0.003
-
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China. Expert Rev Vaccines. 2017 11; 16(11):1155-1169.
Score: 0.003
-
Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans. Vaccine. 2017 10 09; 35(42):5644-5652.
Score: 0.003
-
A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine. Vaccine. 2017 09 05; 35(37):5073-5080.
Score: 0.003
-
Identification and genetic characterization of a novel circular single-stranded DNA virus in a human upper respiratory tract sample. Arch Virol. 2017 Nov; 162(11):3305-3312.
Score: 0.003
-
Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017 03; 5(3):e324-e334.
Score: 0.003